Allcyte is a biotech start-up company focused on functional drug testing in primary human material. With our Pharmacoscopy high-content imaging platform, our mission is to bring the next generation of personalized medicine to cancer patients and treating physicians, and support pharmaceutical companies to focus their drug development efforts on the right molecules in the right indications.
We enable research through the image-based quantification of single-cell phenotypes - all performed directly in primary patient material with minimal amounts of manipulation and requiring minimal amounts of sample. We integrate these data using cutting edge methods of statistics and machine learning to generate actionable insights for our customers. Our mission is to help you make the best possible biomedical decisions.
Pharmacoscopy technology breaks the dogma that high-content and high-throughput imaging can only be performed on adherent cell lines. This opens a whole new method of measuring drug action at the single-cell and sub-cellular level over hundreds of parameters, thousands of patients and millions of cells.
Per patient we routinely record more than 5 billion data points. This forms a solid basis for the extraction of individualised, clinically translatable information. Over time, we will accumulate drug response data from thousands of patients - creating a unique and powerful dataset for the development of even better diagnostics, drug repurposing and new target discovery.
We believe that an image of a single cell contains an unlimited amount of data, but just collecting this data is useless. Using custom designed algorithms and expert interpretation, we can make powerful use of the data we collect. Not only by interpreting it in meaningful ways but also by visualizing it properly, making the data all the more insightful.
Allcyte's founding team is made up of visionary scientists from diverse backgrounds who have excelled in their respective fields, and have united under a common goal: To disrupt functional drug testing through "big data" science. This interdisciplinary approach enables us to tackle complex translational problems.
is a highly robust and efficient assay to determine drug effects ex vivo. It analyses drug action at single cell resolution, working with primary patient samples, simulating as close to possible in vivo conditions. Pharmacoscopy can provide a pre-view of how drugs will likely function in real patients enabling physicians and our pharmaceutical partners to make the best possible decision when prioritizing treatments and research.
of images analyzed per year
data points per cell analyzed
Pharmacoscopy supported clinical studies
Pharmacoscopy is highly adaptable to clinical needs.
We understand access to primary patient samples is limited. For this reason, we designed Pharmacoscopy to have minimal sample need. Very often, left-over samples from routine diagnostic biopsies are sufficient. One 9 mL tube of blood or bone marrow can allow us to test up to 1000 different experimental conditions. This is achieved through analyzing and interrogating each and every individual cell within a primary sample in our microscopy images. We think there is no sense in wasting precious primary cells or material.
Using the latest in screening technology, and our own software and analysis algorithms, we can detect very early phenotypes requiring only short incubation periods, no outgrowth of clonal cell populations, and no sample manipulation. Thus enabling a feedback loop of data either to our medical partners or our research partners efficiently and with the accuracy that translational medicine mandates.
Pharmacoscopy allows us to study cell-autonomous phenotypes and gain a preview of how these cells will likely respond to anticancer drugs in the patient. But it does not end there: For the first time, we can also interrogate the interplay of different cell types in complex mixtures with high resolution. By measuring cell-cell interactions, for example, we can quantify immunomodulatory drug phenotypes such as the formation of immunological synapses between cancer and effector cells to study the power of our immune system to fight cancer. Integrating data over large number of patients we can extract useful patterns including: Which drugs could work in which combinations? Is there potential for new off-label uses or repurposing?
Pharmacoscopy directly measures drug response through the most immediate way of analyzing a cell's function: By looking at it. With single cell resolution. This stands in contrast to techniques where drug response is inferred indirectly from proxy parameters. This direct measurement principle makes results from Pharmacoscopy highly translatable. We further work to limit any manipulation to the primary material we use, there is no cell selection, clonal outgrowth, or long incubation times necessary to make the ex vivo results as relevant for the in vivo situation as possible.
Every patient and every cancer responds differently to anticancer therapy. Our mission is to provide treating haematooncologists the tools to make the best possible treatment choice for patients to reduce side-effects from potentially ineffective therapy and improve outcome.
Cell lines do not fully recapitulate the in vivo milieu for individual cells, and many drug candidates fall short of expectations generated by results in preclinical cell line models when reaching human trials. That's why we set out to bridge the translational gap. By testing your anticancer and immune-oncology compounds in real patient samples, we can help understand how drugs will likely perform in real patients or which indication or patient groups to focus on. By comparing ex vivo drug response patterns to sequencing data, we can help you identify biomarker candidates for patient selection even before entering the first clinical study.
We closely work with hematooncologists and understand that treating cancer patients is extremely challenging. It requires careful integration of clinical guidelines, latest scientific research, diagnostic data and the individual situation of a patient. Our mission is to provide you with high performance tools that generate insight into the likely drug response of a patient that go beyond existing risk classification and genetic prediction systems to help you make the best possible treatment decisions.
We are in the process of developing fully certified in vitro diagnostic tests for the personalized treatment of hematological cancer patients. We aim to bring first tests to market by 2020 in the EU. Already now, however, we invite you to join our groundbreaking research effort and can provide you access to our Pharmacoscopy screening platform for research use only. Please contact us for details.